ArticleVirchows Archiv : an international journal of pathology2026
HER2-low metastatic breast cancers: clinic-pathological characteristics, metastatic sites, and survival impact on biomarker discordance.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Trastuzumab Deruxtecan has shown promising results in patients with HER2-low and -ultralow (UL) metastatic breast cancers, attracting extensive research on these tumors. While most studies focus on primary tumors, there is limited data on metastatic disease. Here, we aimed to evaluate the clinicopathological features, metastatic patterns and biomarker discordance in HER2-low/UL metastatic breast cancers. The HER2 status in a large cohort of metastatic breast cancer cases was correlated with different pathological and survival parameters. Data from matched primary tumours were also retrieved for further comparisons. HER2-low metastatic breast cancer is significantly associated with ER positivity (p = 0.033), PR positivity (p = 0.037) and Luminal status (p = 0.047), but no distinct overall survival. These tumors were preferentially found in liver metastases (42.9%), differing significantly from HER2-zero cancers (p < 0.001). Downregulation of HER2-positive primaries to HER2-negative metastasis was found to be the highest in liver (50.0%), and the least in lung (0%). Downregulation of HER2 is associated with poorer OS (Chi-sq = 9.248, p = 0.002). In metastatic settings, features and survival outcomes of HER2-UL are not significantly distinct from HER2-null tumors. HER2-low metastatic cancers largely retain clinicopathological characteristics of their primary origins. Liver is the predominant site of HER2-low metastasis and shows a notable risk of HER2 discordance. Given that discordance, particularly the link of worse outcome to HER2 downregulation, re-evaluation of biomarker status in high-risk sites should be considered to optimise therapeutic strategies.
Indexed as
Identifiers
42730841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.